Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Dr. David Rubin discusses what IBD patients can do if they are asked to stop immunosuppressant treatment because of COVID-19.
Inflammatory bowel disease (IBD) patients who contract the coronavirus disease 2019 (COVID-19) are recommended to halt their immunosuppressant treatments, but what alternatives do they have to not worsen the IBD condition?
In an interview with HCPLive®, David T. Rubin, MD, University of Chicago Medicine Inflammatory Bowel Disease Center, discusses some of the options for these patients and what researchers have learned about how COVID-19 results in some gastrointestinal symptoms.